Avalia - Model AVA2002 - Malaria Prevention Vaccine
An effective malaria preventative vaccine is considered to be the most important modality to prevent the transmission and occurrence of malaria. Avalia’s malaria vaccine programme aims to develop a more efficacious preventative vaccine to protect individuals from being infected by the malaria parasite (Plasmodium).
-
Most popular related searches
Details
In 2016, there were 216 million cases of malaria in 91 countries, 5 million more than the previous year. Despite significant disease management programmes, malaria continues to claim a significant number of lives and in 2016, 445 000 people died globally.
Global R&D efforts are intense, but despite this, there is currently no licensed malaria vaccine. Our preclinical research efforts alongside our collaborators has shown that activating NKT cells using Avalia’s vaccines generate higher numbers of liver-resident memory T cells and protect against malaria infection.
Customer reviews
No reviews were found for Avalia - Model AVA2002 - Malaria Prevention Vaccine. Be the first to review!